- Home
- OPHC vs FATE Comparison
OPHC vs FATE Comparison
Compare OPHC & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | FATE |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.1M | 125.6M |
| IPO Year | 2012 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OPHC | FATE |
|---|---|---|
| Price | $8.69 | $2.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $10.92 | $5.74 |
| AVG Volume (30 Days) | 79.7K | ★ 1.4M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $0.95 |
| 52 Week High | $10.68 | $3.23 |
Technical Indicators
Market Signals| Indicator | OPHC | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 42.27 |
| Support Level | $8.57 | $2.27 |
| Resistance Level | $9.31 | $2.62 |
| Average True Range (ATR) | 0.35 | 0.14 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 13.36 | 14.46 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.